BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
Phase 3negativeBNT113Negative
AI Analysis
Summary
BioNTech's BNT113 failed to improve progression-free survival in a Phase 3 trial for head and neck cancer, marking the company's third mRNA setback. The company hopes for an overall survival benefit, though analysts consider this outcome less likely.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
failed to improve progression-free survival
Importance:8/10
Sentiment:
-0.75
mRNAoncologyclinical_failurehead_and_neck_cancersetback
Related Companies
Read the original article
Published by BioSpace on October 13, 2026 3:00 PM